DJIA 17,131.97 100.83 0.59%
NASDAQ 4,552.76 33.86 0.75%
S&P 500 1,998.98 14.85 0.75%
market minute promo

Alnylam Pharmaceuticals (NASDAQ: ALNY)

company name or ticker

Down 17%: Is Isis Pharmaceuticals Worth Buying Now?

Despite a deep product pipeline of intriguing RNAi drugs, shares in Isis (ISIS) have toppled this year. Here's what you need to know about Isis and the catalysts likely to move its shares in the coming year.

Why Alnylam Pharmaceuticals (ALNY) Stock is Down Today

Alnylam Pharmaceuticals (ALNY) Showing Signs Of A Dead Cat Bounce Today

Thursday Sector Laggards: Biotechnology, Drugs

Thursday's ETF Movers: THRK, XBI

EPO Upholds Alnylam's McSwiggen Patent - Analyst Blog

In A Shaky Biotech Market, Alnylam's Prospects Are Getting Stronger

Today’s Top Biotech Stories: MannKind, GSK, Myriad, and Alnylam

MannKind, GlaxoSmithKline, Myriad Genetics, and Alnylam Pharmaceuticals could all make waves in the biotech sector this morning.

UPDATE: Alnylam Receives Positive Opinion for Orphan Drug Designation in EU for ALN-TTRsc

Why American Capital Ltd., Alnylam Pharmaceuticals Inc., and Micron Technology Inc. are Today's 3 Be

Comments from Fed Chairwoman Janet Yellen help stocks across the market rise
See More Articles...